Platelet hyperactivity after statin treatment discontinuation

Summary

Hydroxymethyl-glutaryl-CoA-reductase inhibitors (statins) reduce cardiovascular events by cholesterol lowering as well as by non-lipid related actions. Among them, the modulation of platelet activity could play a relevant role in vascular protection. Furthermore withdrawal of statins has been associated with increased cardiovascular event rate. The aim of our study was to evaluate platelet activity after cerivastatin discontinuation in eighteen subjects that did not accept other drugs and in sixteen subjects continuing treatment with simvastatin. Fourteen subjects at the end of the discontinuation period decided to receive other drugs (simvastatin) and they were evaluted six weeks later. We measured complete lipid profile by the chromogenic method (LDL-C was calculated); oxidized-LDL (ox-LDL; ELISA), platelet P-selectin (P-sel) expression (flow cytometry detection), platelet aggregation (% change of transmitted light), intracellular citrullin production (iCit; HPLC) as an indicator of intracellular NO synthase activity at baseline and 7, 14, 28, 60 days after statin discontinuation. P-sel expression and platelet aggregation were increased at 14 days (p< 0.001 and p< 0.05) in association with raised ox-LDL (r= 0.30, p< 0.05) and decreased iCit (r= 0.53, p< 0.01). Increased LDL-C was related to P-sel and platelet aggregation at 28 days (r= 0.30, p< 0.05). Subjects continuing statin treatment had no significant changes of P-sel at 28 (p= 0.221) and 60 days (p=0.238). Subjects treated with simvastatin after 60 days of diet showed a significant reduction of P-sel and platelet aggregation after six weeks of treatment (p< 0.01).

Our data suggest a platelet hyperactivation state in the second week after statin discontinuation which is partially related to raised LDL-C. Such a finding could participate in the increased cardiovascular event rate after statin discontinuation.

Keywords

Statins - platelets - hypercholesterolemia - atherothrombosis

• References

• 1 Bolego C, Baetta R, Bellosta S. et al. Safety considerations for statins. Curr Opin Lipidol 2002; 13: 637-44.
• 2 Vaughan CJ, Gotto jr AM, Basson CT. (1999) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10.
• 3 Neaton JD, Blackburn H, Jacobs D.. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-1500.
• 4 Comparato C, Altana C, Bellosta S. et al. Clinically relevant pleiotropic effects of sta-tins: drug properties or effects of profound cholesterol reduction?. Nutr Metab Cardiovasc Dis 2001; 11: 328-43.
• 5 Hiatt JG, Shamsie SG. Schetctman. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999; 5: 437-44.
• 6 Ruof J, Klein G, Marz W. et al. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002; 35: 48-53.
• 7 Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high. BMJ 2000; 321: 1084.
• 8 Heeschen C, Hhamm CW, Laufs U. et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Circulation 2002; 105: 1446-52.
• 9 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
• 10 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hypercholesterolemic subjects. Eur J Clin Invest 2002; 32: 901-908.
• 11 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 2001; 285: 2486-97.
• 12 ICJME. Sponsorship, Authorship and Accountability. N Engl J Med 2001; 345: 825-8.
• 13 Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3-11.
• 14 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-503.
• 15 Ferroni P, Speziale G, Ruvolo G. et al. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass. A possible correlation?. Thromb Haemost 1998; 80: 58-64.
• 16 Chen LY, Metha P, Metha JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function. Circulation 1996; 93: 1740-6.
• 17 Heart protection study collaborative group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,356 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
• 18 Prisco D, Rogasi PG, Paniccia R. et al. Altered lipids composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thromb Res 1988; 50: 593-604.
• 19 Nofer JR, Tepel M, Kehrel B. et al. Low-density lipoproteins inhibit the Na⁺/H⁺ antiport in human platelets. A novel mechanism of enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95: 1370-7.
• 20 Hussein O, Schlezinger S, Rosenblat M. et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to LDL. Atherosclerosis 1997; 128 (11) 18.
• 21 Aviram M, Hussein O, Rosenblat M. et al. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: anti-atherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39-45.
• 22 Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992; 93: 105-13.
• 23 Kleinveld HA, Demacker PN, De Haan AF, Stalenhoef AF. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993; 23: 289-95.
• 24 Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 335-8.
• 25 Girona J, La Ville AE, Sola R. et al. Simvastatin decrease aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-51.
• 26 Kratz M, Cullen P, Kannenberg F. et al. Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Eur J Clin Nutr 2002; 56: 72-81.
• 27 Vlasova II. The effect of oxidatively modified low-density lipoproteins on platelet aggregability and membrane fluidity. Platelets 2000; 11: 406-14.
• 28 Zhao B, Dierichs R, Miller FN, Dean WL. Oxidized low density lipoprotein inhibits platelet plasma membrane Ca²⁺-ATPase. Cell Calcium 1996; 19: 453-8.
• 29 Puccetti L, Bruni F, Bova G. et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 2001; 11: 378-87.
• 30 Tannous M, Cheung R, Vignini A, Mutus B.. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999: 1390-4.
• 31 Dujovne CA, Harris WS, Altman R. et al. Effect of atorvastatin on hemorheologichemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000; 85: 350-3.
• 32 Broijersen A, Eriksson M, Leijd B. et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 273-8.
• 33 Schror K, Lobel P, Steinhangen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989; 2: 39-45.
• 34 Takahashi Y, Fuda H, Yanai H. et al. Significance of membrane glycoproteins in platelet interaction with oxidized low-density lipoprotein. Sem Thromb Haemost 1998; 24: 251-3.